Chronic kidney disease is a state of hyperaldosteronism, as observed in our patients.Studies have indicated the benefit of using MR antagonists for cardiovascularoutcomes, both in the general population and in patients with CKD.12,13 Furthermore, it has been demonstrated experimentally that MR blockingis capable of modifying pathways involved in the development of VC.8 These observations raise the followingquestion: is the cardiovascular benefit of MR antagonists also related to thedevelopment and progression of CC? The gene discussed is NR3C2; the disease is hyperaldosteronism.